Posts Tagged ‘canagliflozin’

January 14th, 2013

Advisory Panel Recommends Approval of Diabetes Drug Canagliflozin

An advisory committee to the FDA recommended approving canagliflozin, a new type of drug for type 2 diabetes, late last week, the New York Times reports. The once-daily oral drug is a selective sodium glucose co-transporter 2 inhibitor. It prevents reabsorption of glucose by the kidney, thereby increasing glucose excretion in the urine and reducing blood […]